A comparative study of neuroprotective effect of single and combined blockade of AT1 receptor and PARP-1 in focal cerebral ischaemia in rat

International Journal of Stroke

Volumn 9, Issue 5, 2014, Pages 560-568

  Singh, Neetu ^a   Sharma, Gaurav ^a   Singh, Nilendra ^a   Hanif, Kashif ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Angiotensin AT1 receptor; Candesartan; Cerebral ischaemia; Isoquinolinediol; PARP 1

Indexed keywords

1,5 ISOQUINOLINEDIOL; ANGIOTENSIN 1 RECEPTOR; CANDESARTAN HEXETIL; GLUTATHIONE; MALONALDEHYDE; NEUROPROTECTIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1 INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITRITE; REACTIVE OXYGEN METABOLITE; TRIPHENYLTETRAZOLIUM; UNCLASSIFIED DRUG; 1,5-DIHYDROXYISOQUINOLINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; COLORING AGENT; ISOQUINOLINE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, RAT; TETRAZOLE DERIVATIVE; TETRAZOLIUM;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN LEVEL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; MALE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; RECEPTOR BLOCKING; REPEATED DRUG DOSE; REPERFUSION; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; COMPARATIVE STUDY; DIAGNOSTIC USE; DRUG COMBINATION; DRUG EFFECTS; INFARCTION, MIDDLE CEREBRAL ARTERY; METABOLISM; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BRAIN; BRAIN EDEMA; COLORING AGENTS; DRUG THERAPY, COMBINATION; INFARCTION, MIDDLE CEREBRAL ARTERY; ISOQUINOLINES; MALE; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; OXIDATIVE STRESS; POLY(ADP-RIBOSE) POLYMERASES; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; TETRAZOLES; TETRAZOLIUM SALTS;

EID: 84901979269     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2012.00916.x     Document Type: Article

References (57)

1. Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology 2008; 55:310-318.
2. Mehta SL, Manhas N, Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 2007; 54:34-66.
3. Culman J, Baulmann J, Blume A, Unger T. The renin-angiotensin system in the brain: an update. J Renin Angiotensin Aldosterone Syst 2001; 2:96-102.
4. Saavedra JM. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol 2005; 25:485-512.
5. de GM, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52:415-472.
6. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 2003; 12:70-88.
7. Stenman E, Edvinsson L. Cerebral ischemia enhances vascular angiotensin AT1 receptor-mediated contraction in rats. Stroke 2004; 35:970-974.
8. Groth W, Blume A, Gohlke P, Unger T, Culman J. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. J Hypertens 2003; 21:2175-2182.
9. Ito T, Nishimura Y, Saavedra J. Pre-treatment with candesartan protects from cerebral ischaemia. J Renin Angiotensin Aldosterone Syst 2001; 2:174-179.
10. Ito T, Yamakawa H, Bregonzio C, Terron JA, Falcon-Neri A, Saavedra JM. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 2002; 33:2297-2303.
11. Engelhorn T, Goerike S, Doerfler A etal. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab 2004; 24:467-474.
12. Hosomi N, Nishiyama A, Ban CR etal. Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience 2005; 134:225-231.
13. Beckman JS, Ischiropoulos H, Zhu L etal. Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch Biochem Biophys 1992; 298:438-445.
14. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312:159-163.
15. Endres M, Wang ZQ, Namura S etal. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase. J Cereb Blood Flow Metab 1997; 17:1143-1151.
16. Ikeda Y, Hokamura K, Kawai T etal. Neuroprotective effects of KCL-440, a new poly(ADP-ribose) polymerase inhibitor, in the rat middle cerebral artery occlusion model. Brain Res 2005; 1060:73-80.
17. Koh SH, Park Y, Song CW etal. The effect of PARP inhibitor on ischaemic cell death, its related inflammation and survival signals. Eur J Neurosci 2004; 20:1461-1472.
18. Lee JH, Park SY, Shin HK etal. Poly (ADP-ribose) polymerase inhibition by cilostazol is implicated in the neuroprotective effect against focal cerebral ischemic infarct in rat. Brain Res 2007; 1152:182-19.
19. Komjáti K, Mabley JG, Virag L, Southan GJ, Salzman AL, Szabó C. Poly(ADP-ribose) polymerase inhibition protect neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke. Int J Mol Med 2004; 13:373-382.
20. Ding Y, Zhou Y, Lai Q, Li J, Gordon V, Diaz FG. Long-term neuroprotective effect of inhibiting poly (ADP-ribose) polymerase in rats with middle cerebral artery occlusion using a behavioral assessment. Brain Res 2001; 915:210-217.
21. Strosznajder RP, Gadamski R, Czapski GA, Jesko H, Strosznajder JB. Poly(ADP-ribose) polymerase during reperfusion after transient forebrain ischemia: its role in brain edema and cell death. J Mol Neurosci 2003; 20:61-72.
22. Gupta S, Kaul CL, Sharma SS. Neuroprotective effect of combination of poly (ADP-ribose) polymerase inhibitor and antioxidant in middle cerebral artery occlusion induced focal ischemia in rats. Neurol Res 2004; 26:103-107.
23. Kabra DG, Thiyagarajan M, Kaul CL, Sharma SS. Neuroprotective effect of 4-amino-1, 8-napthalimide, a poly(ADP ribose) polymerase inhibitor in middle cerebral artery occlusion-induced focal cerebral ischemia in rat. Brain Res Bull 2004; 62:425-433.
24. Sharma SS, Munusamy S, Thiyagarajan M, Kaul CL. Neuroprotective effect of peroxynitrite decomposition catalyst and poly(adenosine diphosphate-ribose) polymerase inhibitor alone and in combination in rats with focal cerebral ischemia. J Neurosurg 2004; 101:669-675.
25. Mishra V, Verma R, Singh N, Raghubir R. The neuroprotective effects of NMDAR antagonist, ifenprodil and ASIC1a inhibitor, flurbiprofen on post-ischemic cerebral injury. Brain Res 2011; 1389:152-160.
26. Raghubir R, Verma R, Samuel SS, Raza S, Haq W, Katti SB. Anti-stroke profile of thiazolidin-4-one derivatives in focal cerebral ischemia model in rat. Chem Biol Drug Des 2011; 78:445-453.
27. Schumacher J, Puchakayala MR, Binkowski K, Eichler W, Dendorfer A, Klotz KF. Effects of candesartan and enalaprilat on the organ-specific microvascular permeability during haemorrhagic shock in rats. Br J Anaesth 2006; 96:437-443.
28. Stenman E, Jamali R, Henriksson M, Maddahi A, Edvinsson L. Cooperative effect of angiotensin AT(1) and endothelin ET(A) receptor antagonism limits the brain damage after ischemic stroke in rat. Eur J Pharmacol 2007; 570:142-148.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-275.
30. Anderson ME. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 1985; 113:548-555.
31. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 1982; 126:131-138.
32. Socci DJ, Bjugstad KB, Jones HC, Pattisapu JV, Arendash GW. Evidence that oxidative stress is associated with the pathophysiology of inherited hydrocephalus in the H-Tx rat model. Exp Neurol 1999; 155:109-117.
33. Fisher M, Hanley DF, Howard G, Jauch EC, Warach S. Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke 2007; 38:245-248.
34. Dai WJ, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999; 30:2391-2398.
35. Nishimura Y, Ito T, Hoe K, Saavedra JM. Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors. Brain Res 2000; 871:29-38.
36. Yamakawa H, Phillips MI, Saavedra JM. Intracisternal administration of angiotensin II AT1 receptor antisense oligodeoxynucleotides protects against cerebral ischemia in spontaneously hypertensive rats. Regul Pept 2003; 111:117-122.
37. Tota S, Kamat PK, Awasthi H etal. Candesartan improves memory decline in mice: involvement of AT1 receptors in memory deficit induced by intracerebral streptozotocin. Behav Brain Res 2009; 199:235-240.
38. Fagan SC, Kozak A, Hill WD etal. Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. J Hypertens 2006; 24:535-539.
39. Brdon J, Kaiser S, Hagemann F, Zhao Y, Culman J, Gohlke P. Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke. J Hypertens 2007; 25:187-196.
40. Abramov AY, Scorziello A, Duchen MR. Three distinct mechanisms generate oxygen free radicals in neurons and contribute to cell death during anoxia and reoxygenation. J Neurosci 2007; 27:1129-1138.
41. Cai H, Griendling KK, Harrison DG. The vascular NAD (P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003; 24:471-478.
42. Lou M, Blume A, Zhao Y etal. Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat. J Cereb Blood Flow Metab 2004; 24:536-547.
43. Sugawara T, Kinouchi H, Oda M, Shoji H, Omae T, Mizoi K. Candesartan reduces superoxide production after global cerebral ischemia. Neuroreport 2005; 16:325-328.
44. Zhou J, Ando H, Macova M, Dou J, Saavedra JM. Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab 2005; 25:878-886.
45. Tokime T, Nozaki K, Sugino T, Kikuchi H, Hashimoto N, Ueda K. Enhanced poly(ADP-ribosyl)ation after focal ischemia in rat brain. J Cereb Blood Flow Metab 1998; 18:991-997.
46. LaPlaca MC, Raghupathi R, Verma A etal. Temporal patterns of poly(ADP-ribose) polymerase activation in the cortex following experimental brain injury in the rat. J Neurochem 1999; 73:205-213.
47. Agardh CD, Zhang H, Smith ML, Siesjo BK. Free radical production and ischemic brain damage: influence of postischemic oxygen tension. Int J Dev Neurosci 1991; 9:127-138.
48. Siesjo BK, Agardh CD, Bengtsson F. Free radicals and brain damage. Cerebrovasc Brain Metab Rev 1989; 1:165-211.
49. Andrabi SA, Kim NS, Yu SW etal. Poly (ADP-ribose) (PAR) polymer is a death signal. Proc Nat Acad Sci U S A 2006; 103:18308-18313.
50. Yu SW, Andrabi SA, Wang H etal. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Nat Acad Sci U S A 2006; 103:18314-18319.
51. Kaundal RK, Shah KK, Sharma SS. Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation. Life Sci 2006; 79:2293-2302.
52. Lenzser G, Kis B, Snipes JA etal. Contribution of poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats. J Cereb Blood Flow Metab 2007; 27:1318-1326.
53. Kauppinen TM, Suh SW, Berman AE, Hamby AM, Swanson RA. Inhibition of poly(ADP-ribose) polymerase suppresses inflammation and promotes recovery after ischemic injury. J Cereb Blood Flow Metab 2009; 29:820-829.
54. Bohlender J, Gerbaulet S, Kramer J, Gross M, Kirchengast M, Dietz R. Synergistic effects of AT(1) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model. Hypertension 2000; 35:992-997.
55. Pratap R, Pillai KK, Khanam R, Islam F, Ahmad SJ, Akhtar M. Protective effect of irbesartan, an angiotensin II receptor antagonist, alone and in combination with aspirin on middle cerebral artery occlusion model of focal cerebral ischemia in rats. Hum Exp Toxicol 2011; 30:354-362.
56. Yap E, Tan WL, Ng I, Ng YK. Combinatorial-approached neuroprotection using pan-caspase inhibitor and poly (ADP-ribose) polymerase (PARP) inhibitor following experimental stroke in rats; is there additional benefit? Brain Res 2008; 1195:130-138.
57. Schrader J, Lüders S, Kulschewski A etal. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34:1699-1703.